Clinical trials: Antiviral Treatment
Liver Cirrhosis, Chronic Hepatitis B
Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)
Antiviral treatment on Chronic Hepatitis B (CHB) patients with liver cirrhosis is compulsory and effective. Telbivudine, which is superior to lamivudine in the treatment of CHB,is considered to be appropriate for the antiviral…
- Trial name
- NCT01380951
- Testing
- telbivudine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The Fifth People's Hospital of Suzhou
Hepatitis B Virus Infection, Pregnancy
The Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test
Since the implementation of universal vaccination in 1984, the chronic HBV carier rate in our general population reduced from 15-20%, down to < 1% in the post-vaccination population.
- Trial name
- NCT01312012
- Testing
- antiviral therapy
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Hepatitis Viruses
PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis
Hepatitis C virus (HCV) infection is common in patients receiving hemodialysis. The uptake of antiviral therapy for these patients is limited in the era of interferon (IFN) plus ribavirin (RBV), probably because the sustained…
- Trial name
- PIVOTAL (NCT02874066)
- Testing
- PTV/r/OBV/DSV
- Where
- 8 sites in Taiwan
- Volunteers
- 46 people
- Sponsor
- National Taiwan University Hospital
Liver Disease
Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
More than 1.5 millions individuals are infected with HCV in Italy. They are at risk to develop related morbidity and mortality from cirrhosis and hepatocellular carcinoma, unless the evolution of their disease is halted by…
- Trial name
- NCT01437969
- Testing
- genotyping and/or sequencing
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
HIV Infections
A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time
To study the toxicity, pharmacokinetics, and antiretroviral effectiveness of combined oral zidovudine (AZT) and intermittent intravenous foscarnet therapy in stable AIDS or AIDS related complex (ARC) patients who have already…
- Trial name
- NCT00001002
- Testing
- Zidovudine, Foscarnet sodium
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, HBV
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B e antigen (HBeAg)-negative subjects with chronic HBV infection.
- Conditions
- Hepatitis B, HBV, Hepatitis B, Chronic
- Trial name
- NCT04023721
- Testing
- Inarigivir soproxil, Nucleoside/nucleotide (NUC) analogue inhibitors
- Where
- 7 sites in Canada, United Kingdom
- Volunteers
- 64 people
- Sponsor
- F-star Therapeutics, Inc.
HIV Infections
Antiviral Therapy and HIV in the Female Genital Tract
HIV is found in both the blood and the genital tract. This study will compare the levels and types of HIV found in the blood with the levels and types of HIV found in the female genital tract.
- Trial name
- NCT00067106
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs
To evaluate the antiviral activity and safety of two formulations of saquinavir in combination with licensed nucleoside antiretroviral drugs.
- Trial name
- NCT00002162
- Testing
- Saquinavir, Lamivudine, Stavudine
- Where
- 27 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
COVID-19
Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection
Flonoltinib Maleate (FM) is a triple-target inhibitor of JAK2, FLT3, and CDK6. It inhibited JAK2 with an IC50 of 0.8 nM, whereas its IC50 values against JAK1, JAK3, and TYK2 were 690 nM, 557 nM, and 65 nM, respectively…
- Trial name
- NCT05713279
- Testing
- SOC
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Drug-Induced Liver Injury
Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs
Case control Study to assess the difference of immune cell responses between patients with chronic HCV- related liver cirrhosis who develop HCC after treatment with DAAs and those who do not develop HCC
- Trial name
- NCT03602703
- Testing
- Flow cytometry and Western Blot analysis
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Assiut University
HIV/AIDS
A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults
This is a Phase 1/2a open label study to evaluate the safety, tolerability, pharmacokinetics and anti-viral activity of PGT121, VRC07-523LS and PGDM1400 for HIV prevention and therapy.
- Trial name
- NCT03721510
- Testing
- PGT121 + VRC07-523LS, PGT121 + VRC07-523LS + PGDM1400
- Where
- 3 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Hepatitis B
Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy
The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Positive lymphoma patients treated with rituximab-based immunochemotherapy.
- Trial name
- NCT01768195
- Testing
- Entecavir prophylaxis
- Where
- 13 sites in China
- Volunteers
- 80 people
- Sponsor
- Peking University
Chronic Hepatitis C
Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil
The study is a non-randomized, single group clinical trial on monitoring hepatitis C therapy using telemedicine. Patients with chronic hepatitis C without cirrhosis will be treated with the pangenotypic regimen of direct acting…
- Trial name
- NCT04039698
- Testing
- Telemedicine, Velpatasvir/Sofosbuvir
- Where
- Brazil
- Volunteers
- 144 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
HIV Infections
GW873140 to Treat HIV-1 Infected Adults
This study will determine which of four doses of GW873140 can safely be given to adults to lower the amount of virus (HIV-1) in the body. GW873140 is a new type of anti-HIV drug called a CCR5 receptor antagonist.
- Trial name
- NCT00076284
- Testing
- GW873140
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Retinitis, HIV Infections
A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis
To determine the MTD and dose-limiting toxicities of a regimen of therapeutic ganciclovir, antiretroviral therapy, and recombinant interleukin-2 (aldesleukin; Proleukin) as an immune adjuvant in HIV-seropositive patients.
- Trial name
- NCT00002321
- Testing
- Aldesleukin
- Where
- United States
- Sponsor
- Chiron Corporation
Hepatitis C
Reaching mEthadone Users Attending Community pHarmacies With HCV
Hepatitis C Virus (HCV) is a blood-borne virus that damages the liver and is a major public health threat globally. Most individuals infected with HCV are unaware of it and show no symptoms until presenting with incurable, fatal…
- Trial name
- REACH-HCV (NCT03935906)
- Testing
- Reach Pathway, Education-only Pathway
- Where
- 3 sites in Australia, United Kingdom
- Volunteers
- 1,410 people
- Sponsor
- University of Dundee
Chronic Hepatitis B, COVID-19 Infection
Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy
This is a two-way (retrospective and prospective) study of COVID-19 infection in an observational cohort of patients with chronic hepatitis B treated with antiviral therapy.
- Trial name
- NCT05792878
- Testing
- Interferon, nucleoside analogues
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Beijing Ditan Hospital
Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of
HCV Reinfection in HD Patients Achieving SVR
Among the hemodialysis units, the global incidence of HCV infection ranges from 1.2% to 2.9%. Data regarding the long-term risk of reinfection among hemodialysis patients achieving SVR are limited.
- Conditions
- Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Hemodialysis Complication
- Trial name
- NCT04732832
- Where
- 7 sites in Taiwan
- Volunteers
- 350 people
- Sponsor
- National Taiwan University Hospital
HIV-1-infection
Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)
The purpose of this study is to demonstrate the effectiveness of Symtuza® in a rapid reinitiation model of care in patients with HIV-1 infection and who are treatment-experienced but have been off of antiretroviral therapy (ART)…
- Trial name
- ReSTART (NCT04388904)
- Testing
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- The Crofoot Research Center, Inc.
HIV Infections
The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
To compare the durability of the viral load response following 48 weeks of treatment with 1592U89/lamivudine (3TC)/zidovudine (ZDV) versus 3TC/ZDV alone.
- Trial name
- NCT00002389
- Testing
- Abacavir sulfate, Lamivudine, Zidovudine
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 210 people
- Sponsor
- Glaxo Wellcome